Recent reports have now implicated interleukin 12 and interleukin 23 ... The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2 ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

J&J’s pharma unit Janssen said Stelara is the first interleukin-12/23 inhibitor to be approved for UC, an inflammatory bowel disease which affects around 2.6 million people in Europe.

Stelara, also known as ustekinumab, is a monoclonal antibody that targets specific proteins called interleukin-12 (IL-12) and ...

ustekinumab, or a placebo. Mirikizumab is an engineered monoclonal antibody already approved for treating ulcerative colitis. Mirikizumab targets and inhibits the p19 subunit of interleukin-23 ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...

Stelara. Europes CHMP scientific committee approved the label update for Cosentyx (secukinumab), the first interleukin-17A approved to treat psoriasis. Sales of Cosentyx, which is injected every ...

Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune ...

Imuldosa® was already approved by the USFDA on October 10, 2024. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which may play an important ...